Genexine Advances DNA Vaccine With Mid-Stage Cervical Cancer Success
In Regimen With Keytruda
Executive Summary
The Korean firm’s DNA vaccine has shown promise in a Phase II cervical cancer trial in combination with Merck’s Keytruda, prompting the firm to tout potential in the difficult PD-1 negative group.
You may also be interested in...
From Science To Commercialization: How Genexine Is Making The Shift
Genexine CEO Neil Warma talks to Scrip in this audio interview about a wide range of topics, including key strategy changes, ambitions to become a leading global biopharma, as well as challenges he has faced since joining the Korean biotech.
INTERVIEW: Genexine Aiming To Become Global Player
Genexine is set to progress and expand this year the clinical development of its leading assets, orphan disease drugs and cancer immunotherapies. The South Korean biotech company's CEO talks in an interview with PharmAsia News about its R&D and business strategies, as well as the challenges faced by the wider Korean biotech industry.